Pacira BioSciences (NASDAQ:PCRX – Get Free Report) is scheduled to announce its earnings results after the market closes on Tuesday, July 30th. Analysts expect the company to announce earnings of $0.73 per share for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link.
Pacira BioSciences (NASDAQ:PCRX – Get Free Report) last announced its quarterly earnings data on Tuesday, May 7th. The company reported $0.42 EPS for the quarter, missing the consensus estimate of $0.46 by ($0.04). The business had revenue of $167.12 million during the quarter, compared to the consensus estimate of $165.43 million. Pacira BioSciences had a net margin of 10.34% and a return on equity of 12.98%. On average, analysts expect Pacira BioSciences to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.
Pacira BioSciences Trading Up 0.3 %
Shares of PCRX opened at $20.03 on Monday. Pacira BioSciences has a 1-year low of $19.34 and a 1-year high of $40.16. The firm has a market capitalization of $932.40 million, a price-to-earnings ratio of 14.01 and a beta of 0.88. The company has a 50-day moving average of $26.02 and a 200 day moving average of $28.21. The company has a debt-to-equity ratio of 0.57, a current ratio of 5.81 and a quick ratio of 4.78.
Insider Activity
Analyst Upgrades and Downgrades
PCRX has been the topic of several research reports. Needham & Company LLC reissued a “buy” rating and issued a $43.00 target price on shares of Pacira BioSciences in a research report on Tuesday, July 2nd. Piper Sandler reiterated an “overweight” rating and issued a $42.00 target price on shares of Pacira BioSciences in a research report on Wednesday, July 3rd. Barclays downgraded shares of Pacira BioSciences from an “overweight” rating to an “equal weight” rating and dropped their price objective for the company from $38.00 to $25.00 in a report on Wednesday, July 3rd. Truist Financial cut their price target on Pacira BioSciences from $45.00 to $30.00 and set a “buy” rating on the stock in a research report on Thursday. Finally, HC Wainwright restated a “buy” rating and issued a $57.00 target price on shares of Pacira BioSciences in a research note on Tuesday, July 2nd. One equities research analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $43.60.
Read Our Latest Stock Analysis on PCRX
About Pacira BioSciences
Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.
See Also
- Five stocks we like better than Pacira BioSciences
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- Verizon Stock: 4 Reasons to Buy This Bargain After Recent Dip
- Learn Technical Analysis Skills to Master the Stock Market
- Why a Weaker Dollar is Good News for These 3 Stocks
- How to Find Undervalued Stocks
- Why Bank of America Just Approved a Huge Stock Buyback Program
Receive News & Ratings for Pacira BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.